Cell therapy approaches for lung diseases: current status

Current Opinion in Pharmacology

Volumn 9, Issue 3, 2009, Pages 268-273

  Sueblinvong, Viranuj ^a   Weiss, Daniel J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; STEROID;

ACUTE LUNG INJURY; BONE MARROW; CELL THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROHN DISEASE; DISEASE EXACERBATION; DISEASE MODEL; EMBRYONIC STEM CELL; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG DEVELOPMENT; LUNG DISEASE; LUNG FIBROSIS; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REMISSION; REVIEW; SAFETY; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE REPAIR; UMBILICAL CORD BLOOD;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; LUNG DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TISSUE ENGINEERING;

EID: 65749107312     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.03.002     Document Type: Review

References (52)

1. Weiss D.J., Kolls J.K., Ortiz L.A., Panoskaltsis-Mortari A., and Prockop D.J. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 5 (2008) 637-667. This article by Weiss et al. is a comprehensive summary of a conference entitled 'Stem Cells and Cell Therapies in Lung Biology and Lung Diseases' with extensive review of recent literature related to cell therapy for lung diseases. This includes the current status of structure engraftment by exogenous stem cells, new development related to lung tissue engineering, and the immunomodulation role of mesenchymal stem cells in lung injury. We would recommend this article as an overview review of current status of cell therapy for lung diseases field.
2. Sueblinvong V., Loi R., Eisenhauer P.L., Bernstein I.M., Suratt B.T., Spees J.L., and Weiss D.J. Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med 177 (2008) 701-711. This article by Sueblinvong et al. reported the use of cord blood as a source of mesenchymal stem cells. The authors reported approximately 39% of human cord blood sample yield mesenchymal stem cells (MSC). After characterization, they subsequently injected stem cells into NOD/SCID mice following low dose irradiation. They reported small number of human-derived airway epithelial cells up to three months following the injection. This study demonstrated that MSCs obtained from human umbilical cord blood can engraft NOD/SCID mice airway following low dose irradiation. However, the yield of engraftment is not significantly better than that achieved with bone marrow-derived MSCs. Although this study did not show benefit of MSCs derived from cord blood over bone marrow cells, this is a well-designed study.
3. Loi R., Beckett T., Goncz K.K., Suratt B.T., and Weiss D.J. Limited restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow-derived cells. Am J Respir Crit Care Med 173 (2006) 171-179
4. Marsboom G., and Janssens S. Endothelial progenitor cells: new perspectives and applications in cardiovascular therapies. Expert Rev Cardiovasc Ther 6 (2008) 687-701. This article by Marsboom et al. reviewed literature over the past 10 years on endothelial progenitor cells (EPC) and their role in cardiovascular diseases. The field of EPCs has advanced rapidly and now, although limited, there are clinical trials underway including pilot trial in patients with pulmonary hypertension. This is an excellent review on EPCs and related translational research.
5. Fadini G.P., Schiavon M., Rea F., Avogaro A., and Agostini C. Depletion of endothelial progenitor cells may link pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 176 (2007) 724-725 author reply 725
6. Wang X.X., Zhang F.R., Shang Y.P., Zhu J.H., Xie X.D., Tao Q.M., and Chen J.Z. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 49 (2007) 1566-1571
7. Zhu J.H., Wang X.X., Zhang F.R., Shang Y.P., Tao Q.M., and Chen J.Z. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: Open-label pilot study. Pediatr Transplant 12 (2008) 650-655. This article by Zhu et al. is done to look at the safety and efficacy of autologous endothelial progenitor cells (EPC) transplantation in children with idiopathic pulmonary arterial hypertension (IPAH). This group from China previously reported potential benefit of autologous EPC transplantation in adult with IPAH (see reference [6]). This study was performed with 13 children with IPAH receiving intravenous infusion of autologous EPC and found an improvement in functional class based on NYHA classification, 6-min walk distance, mean pulmonary artery pressure, and cardiac output at 12 weeks. This is an interesting study; however, longer follow up time to assess for potential side effects would be required. Further, a larger multi-center trial to establish the efficacy would be important.
8. Nichols J.E., and Cortiella J. Engineering of a complex organ: progress toward development of a tissue-engineered lung. Proc Am Thorac Soc 5 (2008) 723-730. This is an excellent review article by Nichols and Cortiella on the rapid advancing field of lung tissue engineering. This article reviewed the overall tissue engineering with in-depth discussion on issues pertaining to complexity of the lung. It is a well structured and concise review of current status of this field.
9. Tomei A.A., Boschetti F., Gervaso F., and Swartz M.A. 3d collagen cultures under well-defined dynamic strain: a novel strain device with a porous elastomeric support. Biotechnol Bioeng 103 (2009) 217-225. Tomei et al. presented a unique composite matrix and strain device for culturing cells in physiological, mechanically dynamic three-dimensional environment using engineered polyurethane sponge computerized strain device. Over the past few decades, it is well accepted that dynamic stresses and strains have an impact on cells and tissues organization. This study reported a potential device to be used in combination of stem cells for potential tissue engineering of the lung.
10. Uccelli A., Moretta L., and Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 8 (2008) 726-736
11. Iyer S.S., and Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther 8 (2008) 569-581
12. Aliotta J.M., Passero M., Meharg J., Klinger J., Dooner M.S., Pimentel J., and Quesenberry P.J. Stem cells and pulmonary metamorphosis: new concepts in repair and regeneration. J Cell Physiol 204 (2005) 725-741
13. Kotton D.N., Fabian A.J., and Mulligan R.C. Failure of bone marrow to reconstitute lung epithelium. Am J Respir Cell Mol Biol 33 (2005) 328-334
14. Macpherson H., Keir P., Webb S., Samuel K., Boyle S., Bickmore W., Forrester L., and Dorin J. Bone marrow-derived SP cells can contribute to the respiratory tract of mice in vivo. J Cell Sci 118 (2005) 2441-2450. It has been shown that bone marrow-derived cells could contribute to cells of other organs including lung. This study by Macpherson et al. further defined the specific bone marrow cell populations called side population (SP). They demonstrated increased survival among lethally irradiated mice receiving systemic injection of these cells. They found that only 0.8% of tracheal epithelial cells are donor in origin. Although, they did not find an increase in donor-derived cells engrafted in recipient airways as compared to other studies using bone marrow-derived mesenchymal stem cells (MSC) or stromal cells, this study showed that SP might also have the same immunomodulatory effect as MSC as demonstrated by improvement in mortality in lethally irradiated mice received cells.
15. Rojas M., Xu J., Woods C.R., Mora A.L., Spears W., Roman J., and Brigham K.L. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 33 (2005) 145-152
16. Spees J.L., Pociask D.A., Sullivan D.E., Whitney M.J., Lasky J.A., Prockop D.J., and Brody A.R. Engraftment of bone marrow progenitor cells in a rat model of asbestos-induced pulmonary fibrosis. Am J Respir Crit Care Med 176 (2007) 385-394
17. Spees J.L., Whitney M.J., Sullivan D.E., Lasky J.A., Laboy M., Ylostalo J., and Prockop D.J. Bone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertension. FASEB J 22 (2008) 1226-1236
18. Yan C., Lian X., Dai Y., Wang X., Qu P., White A., Qin Y., and Du H. Gene delivery by the hsp-b promoter to lung alveolar type ii epithelial cells in lal-knockout mice through bone marrow mesenchymal stem cells. Gene Ther 14 (2007) 1461-1470
19. Gupta N., Su X., Popov B., Lee J.W., Serikov V., and Matthay M.A. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 179 (2007) 1855-1863
20. Hackett T.L., Shaheen F., Johnson A., Wadsworth S., Pechkovsky D.V., Jacoby D.B., Kicic A., Stick S.M., and Knight D.A. Characterization of side population cells from human airway epithelium. Stem Cells 26 (2008) 2576-2585
21. Herzog E.L., and Krause D.S. Engraftment of marrow-derived epithelial cells: the role of fusion. Proc Am Thorac Soc 3 (2006) 691-695. This is one of the studies that identify fusion as a potential mechanism in which stem cells engrafted and differentiate into airway epithelial cells.
22. Spees J.L., Olson S.D., Ylostalo J., Lynch P.J., Smith J., Perry A., Peister A., Wang M.Y., and Prockop D.J. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc Natl Acad Sci U S A 100 (2003) 2397-2402
23. Zhang Y., Goss A.M., Cohen E.D., Kadzik R., Lepore J.J., Muthukumaraswamy K., Yang J., DeMayo F.J., Whitsett J.A., Parmacek M.S., et al. A gata6-wnt pathway required for epithelial stem cell development and airway regeneration. Nat Genet 40 (2008) 862-870
24. •,22]), this study reported a novel concept of microvesicles for RNA transfer between mature cells and stem cells.
25. Quesenberry P.J., and Aliotta J.M. The paradoxical dynamism of marrow stem cells: considerations of stem cells, niches, and microvesicles. Stem Cell Rev 4 (2008) 137-147
26. Kahler C.M., Wechselberger J., Hilbe W., Gschwendtner A., Colleselli D., Niederegger H., Boneberg E.M., Spizzo G., Wendel A., Gunsilius E., et al. Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury. Respir Res 8 (2007) 50
27. Suzuki H., Hogg J.C., and van Eeden S.F. Sequestration and homing of bone marrow-derived lineage negative progenitor cells in the lung during pneumococcal pneumonia. Respir Res 9 (2008) 25
28. Yan X., Liu Y., Han Q., Jia M., Liao L., Qi M., and Zhao R.C. Injured microenvironment directly guides the differentiation of engrafted flk-1(+) mesenchymal stem cell in lung. Exp Hematol 35 (2007) 1466-1475
29. Epperly M.W., Franicola D., Zhang X., Nie S., Wang H., Bahnson A.B., Shields D.S., Goff J.P., Shen H., and Greenberger J.S. Reduced irradiation pulmonary fibrosis and stromal cell migration in smad3-/- marrow chimeric mice. In Vivo 20 (2006) 573-582
30. Rossignol J., Boyer C., Thinard R., Remy S., Dugast A.S., Dubayle D., Dey N.D., Boeffard F., Delecrin J., Heymann D., et al. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med (2009) [Epub ahead of print]
31. Viswanathan A., Painter R.G., Lanson Jr. N.A., and Wang G. Functional expression of n-formyl peptide receptors in human bone marrow-derived mesenchymal stem cells. Stem Cells 25 (2007) 1263-1269
32. Omori K., Tada Y., Suzuki T., Nomoto Y., Matsuzuka T., Kobayashi K., Nakamura T., Kanemaru S., Yamashita M., and Asato R. Clinical application of in situ tissue engineering using a scaffolding technique for reconstruction of the larynx and trachea. Ann Otol Rhinol Laryngol 117 (2008) 673-678
33. Urita Y., Komuro H., Chen G., Shinya M., Saihara R., and Kaneko M. Evaluation of diaphragmatic hernia repair using plga mesh-collagen sponge hybrid scaffold: an experimental study in a rat model. Pediatr Surg Int 24 (2008) 1041-1045
34. Omori K., Nakamura T., Kanemaru S., Magrufov A., Yamashita M., and Shimizu Y. In situ tissue engineering of the cricoid and trachea in a canine model. Ann Otol Rhinol Laryngol 117 (2008) 609-613
35. A pipe dream becomes reality. Nat Med 15 (2009) 4
36. Andrade C.F., Wong A.P., Waddell T.K., Keshavjee S., and Liu M. Cell-based tissue engineering for lung regeneration. Am J Physiol Lung Cell Mol Physiol 292 (2007) L510-518
37. Mondrinos M.J., Koutzaki S., Lelkes P.I., and Finck C.M. A tissue-engineered model of fetal distal lung tissue. Am J Physiol Lung Cell Mol Physiol 293 (2007) L639-650
38. Mondrinos M.J., Koutzaki S.H., Poblete H.M., Crisanti M.C., Lelkes P.I., and Finck C.M. In vivo pulmonary tissue engineering: contribution of donor-derived endothelial cells to construct vascularization. Tissue Eng Part A 14 (2008) 361-368
39. Cortiella J., Nichols J.E., Kojima K., Bonassar L.J., Dargon P., Roy A.K., Vacant M.P., Niles J.A., and Vacanti C.A. Tissue-engineered lung: an in vivo and in vitro comparison of polyglycolic acid and pluronic f-127 hydrogel/somatic lung progenitor cell constructs to support tissue growth. Tissue Eng 12 (2006) 1213-1225
40. Shigemura N., Okumura M., Mizuno S., Imanishi Y., Matsuyama A., Shiono H., Nakamura T., and Sawa Y. Lung tissue engineering technique with adipose stromal cells improves surgical outcome for pulmonary emphysema. Am J Respir Crit Care Med 174 (2006) 1199-1205
41. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., and Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 8 (2006) 315-317. This article is the latest guidelines for defining mesenchymal stem cell.
42. Ventura C., Cantoni S., Bianchi F., Lionetti V., Cavallini C., Scarlata I., Foroni L., Maioli M., Bonsi L., Alviano F., et al. Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts. J Biol Chem 282 (2007) 14243-14252
43. Lanzoni G., Roda G., Belluzzi A., Roda E., and Bagnara G.P. Inflammatory bowel disease: moving toward a stem cell-based therapy. World J Gastroenterol 14 (2008) 4616-4626
44. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase ii study. Lancet 371 (2008) 1579-1586
45. Prochymal clinical trial information for the treatment of acute GVHD 2008. Available from: http://www.osiris.com/clinical_trials_prochymal_phaseII.php.
46. Ortiz L.A., Dutreil M., Fattman C., Pandey A.C., Torres G., Go K., and Phinney D.G. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 104 (2007) 11002-11007. Ortiz et al. reported a potential mechanism in which mesenchymal stem cells (MSC) attenuate inflammation and fibrosis in bleomycin-induced lung injury. It is one of the first studies to identify a potential molecule produced by MSC. It is a well-designed study. Although, more than one mechanism might be responsible for anti-inflammatory effect by MSC, this article is one of the important article to review in this field.
47. Xu J., Woods C.R., Mora A.L., Joodi R., Brigham K.L., Iyer S., and Rojas M. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 293 (2007) L131-141
48. Xu J., Qu J., Cao L., Sai Y., Chen C., He L., and Yu L. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 214 (2008) 472-481
49. Mei S.H., McCarter S.D., Deng Y., Parker C.H., Liles W.C., and Stewart D.J. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 4 (2007) e269
50. U.S. National institutes of health 2008. http://clinicaltrials.gov, An excellent resource of ongoing clinical trials related to stem cells in variety of diseases including COPD, pulmonary hypertension, etc.
51. Ozawa K., Sato K., Oh I., Ozaki K., Uchibori R., Obara Y., Kikuchi Y., Ito T., Okada T., Urabe M., et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 30 (2008) 121-127
52. Taupin P. Oti-010 osiris therapeutics/jcr pharmaceuticals. Curr Opin Investig Drugs 7 (2006) 473-481